← boardnext 2026-09next 2026-12
DSGN
Design Therapeutics, Inc.distress 1/10 · well-funded / low risk$11.61-1%today-26% from 52w high
Lead: Friedreich Ataxia
Revenue
pre-revenue
Liquidity
$223M
Runway
4.1 yrs
Shares 1y
+10%
Price & events
+9.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-7.9%
1W
-15.5%
1M
-9.2%
3M
+14.0%
6M
+171.9%
1Y
+186.7%
2Y
-36.5%
5Y
-65.9%
All
Overview
- Market Cap
- $725.13M
- Volume
- 15.87K
- 52 Week Range
- $3.82 – $15.79
- Total Shares
- 62.46M
- Float Shares
- 32.87M
- Short %
- 12.13%
- % Held by Insiders
- 31.93%
- % Held by Institutions
- 62.12%
- RVOL
- 0.02x
- Beta
- 1.59
Pipeline stages · 2 programs
DT-168
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DT-216P2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
Catalyst news & presentations · 8
- 2027Guided 40%readoutPhase 1DT-818 · Phase 1 MAD trial resultsSEC 8-K
- second half of 2026Guided 55%readoutPhase 2DT-168 · Phase 2 biomarker trial dataSEC 8-K
- second half of 2026Guided 55%readoutPhase 1/2DT-216P2 · Update on effect on endogenous frataxin levels from RESTORE-FA trialSEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1DT-818 · Begin dosing in Phase 1 MAD trialSEC 8-K
- later in 2025readoutSelection of development candidate for DM1 program.SEC 8-K
- August 7, 2025conferencedata presentationsecondaryPhase 1DT-216P2 · Early human PK data for DT-216P2 demonstrates favorable translation from NHPs to humans.SEC 8-K
- 2025-06-01clinical holdDT-216P2 · FDA clinical hold on U.S. IND for DT-216P2 due to starting dose concerns.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+81% upside) · 6 analysts
- 2026-05-04OppenheimerOutperform
- 2026-03-16JefferiesBuy
- 2026-03-10RBC CapitalOutperform
- 2026-01-07OppenheimerOutperform
- 2025-12-03Leerink PartnersMarket Perform → Outperform
- 2025-11-20RBC CapitalSector Perform → Outperform
Competitors — Friedreich Ataxia
Recent news
- 2026-07-19Design Therapeutics (DSGN) Q1 2026 earnings summary - Quartr
- 2026-07-19Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-19Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary - Quartr
- 2026-07-18Design Therapeutics (DSGN) Proxy filing Summary - Quartr
- 2026-07-18Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
- 2026-07-09DSGN Q1 2026 Earnings: EPS Surprises to the Upside Amid Ongoing Pipeline Development - EPS Surprise History - dars.gov.et
- 2026-07-08Design Therapeutics (DSGN) Jefferies Global Healthcare Conference 2025 Summary - Quartr
- 2026-07-03Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.